GPP
PRQR icon

Great Point Partners’s ProQR Therapeutics PRQR Stock Holding History

Great Point Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,121,122
Closed -$8.98M – 36
2021
Q4 		$8.98M Buy
1,121,122
+1,090,786
+3,596% +$8.31M 2% 23
2021
Q3 		$254K Buy
+30,336
New +$198K 0.06% 36

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Great Point Partners's PRQR Position: Q1 2022 in Review

Great Point Partners sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 1,121,122 shares — an estimated $8.98M sold.

Great Point Partners first reported a position in PRQR in Q3 2021 and held it in 2 quarters. The position peaked at $8.98M in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • Great Point Partners reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Great Point Partners sold 1,121,122 ProQR Therapeutics shares in Q1 2022, an estimated $8.98M.
  • Great Point Partners first reported a position in ProQR Therapeutics in Q3 2021 and held it in 2 quarters.
  • Great Point Partners's ProQR Therapeutics position peaked at $8.98M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.